Idiopathic eosinophilic pneumonia in children: the French experience

Lisa Giovannini-Chami1, Alice Hadchouel, Nadia Nathan

  • 1Pediatric Pulmonology and Allergy Department, Hôpitaux pédiatriques de Nice CHU-Lenval, Nice F-06200, France. giovannini-chami.l@pediatrie-chulenval-nice.fr.

Insights

Idiopathic eosinophilic pneumonia is rare in children. This study details chronic (ICEP) and acute (IAEP) forms, proposing new definitions and highlighting treatment responses and disease progression in pediatric cases.

Area of Science:

  • Pediatric Pulmonology
  • Rare Diseases
  • Respiratory Medicine

Background:

  • Idiopathic eosinophilic pneumonia (IEP) is exceptionally rare in pediatric populations.
  • This study presents the first series detailing idiopathic chronic eosinophilic pneumonia (ICEP) and idiopathic acute eosinophilic pneumonia (IAEP) specifically in children.
  • Understanding these rare lung conditions is crucial for accurate diagnosis and management.

Purpose of the Study:

  • To describe the clinical characteristics and outcomes of pediatric ICEP and IAEP.
  • To propose a specific pediatric definition and classification algorithm for ICEP.
  • To compare pediatric IAEP with adult cases and identify potential triggers.

Main Methods:

  • Retrospective analysis of pediatric ICEP and IAEP cases.
  • Data collected from French Reference Centers for rare pediatric lung diseases.
  • Review of clinical presentations, treatment responses, and disease progression.

Main Results:

  • Five pediatric ICEP cases identified; three showed significant improvement with corticosteroids or immunosuppressants.
  • Two pediatric ICEP cases exhibited persistent interstitial patterns progressing to cystic lesions.
  • Three adolescent IAEP cases reported, one requiring extracorporeal membrane oxygenation.

Conclusions:

  • Pediatric ICEP presents polymorphically, with some cases progressing to cystic changes, blurring lines with interstitial lung diseases.
  • A specific pediatric definition and classification for ICEP are proposed.
  • Pediatric IAEP appears as an inflammatory lung response to acute toxic exposure, primarily tobacco, similar to adults; international collaboration is needed for further research.
Abstract

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
24
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
4.7K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K